Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Head & Neck 2CNS 2Other solid neoplasm 1Myeloid 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1

Interventions

pembrolizumab 84Cisplatin 73Cetuximab 54Radiotherapy 41Nivolumab 31Radiotherapy, Intensity-Modulated 26Docetaxel 26Fluorouracil 23Cyclophosphamide 23Paclitaxel 22fludarabine 19Radiation 18Gemcitabine 18Carboplatin 18Magnetic Resonance Spectroscopy 16Erlotinib Hydrochloride 16durvalumab 15atezolizumab 13fludarabine phosphate 10Radiosurgery 10Specimen Handling 9Interleukin-2 9Drug Therapy 9Biopsy 9130-nm albumin-bound paclitaxel 9budigalimab 8Ipilimumab 8Bortezomib 8tremelimumab 7toripalimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × prexasertib × Head & Neck × Clear all
NCT02555644 2019-02-15

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Eli Lilly and Company

Phase 1 Completed
70 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms

NCT01115790 2016-05-10

A Phase 1 Study in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
150 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡